Ana Dioun Broyles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Dioun Broyles has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Aleena Banerji
Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Mass
2 shared publications- Allison Eaddy Norton
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN
2 shared publications Craig D. Platt
Division of Immunology, Boston Children's Hospital, Boston, Mass
2 shared publicationsJoyce P. Lee
Division of Immunology at Boston Children's Hospital, Boston, Massachusetts
2 shared publicationsMariana Castells
Drug hypersensitivity and Desensitization Center, Brigham and Women's Hospital, Boston, Mass
2 shared publications- Meredith A. Dilley
Division of Immunology at Boston Children's Hospital, Boston, Massachusetts
2 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 5 (2) , 100619
Successful venom immunotherapy in a child with anaphylaxis to Hymenoptera skin testing
- 1 December 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 5 (2) , 100619
Open AccessSuccessful venom immunotherapy in a child with anaphylaxis to Hymenoptera skin testing
- 1 March 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (3) , 1419-1420
Reply to “Penilloate and penicilloate concentrations in practical guidance recommendations”
- 1 March 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (3) , 1419-1420
Reply to “Penilloate and penicilloate concentrations in practical guidance recommendations”
- 1 October 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (9) , S3-S15
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts
- 1 October 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (9) , S3-S15
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts
- 22 February 2019
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 19 (2) , 11
Pediatric Drug Hypersensitivity
Pediatric drug hypersensitivity is a rapidly evolving field. The purpose of this paper is to review the current state of pediatric drug hypersensitivity and highlight new developments in diagnosis and management.
- 22 February 2019
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 19 (2) , 11
Pediatric Drug Hypersensitivity
Pediatric drug hypersensitivity is a rapidly evolving field. The purpose of this paper is to review the current state of pediatric drug hypersensitivity and highlight new developments in diagnosis and management.
- 1 February 2019
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 122 (2) , 148-155
Drug allergy in children and adults
- 1 February 2019
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 122 (2) , 148-155
Drug allergy in children and adults
- 1 February 2019
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (2) , 675-677
Duplicate skin prick testing in the assessment of food allergy
- 1 February 2019
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (2) , 675-677
Duplicate skin prick testing in the assessment of food allergy
- 26 August 2017
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 37 (4) , 713-725
Management of Children with Hypersensitivity to Antibiotics and Monoclonal Antibodies
- 26 August 2017
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 37 (4) , 713-725
Management of Children with Hypersensitivity to Antibiotics and Monoclonal Antibodies
- 27 October 2016
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (5)
Methotrexate hypersensitivity reactions in pediatrics: Evaluation and management
Reports of hypersensitivity reactions (HSRs) to MTX are limited to single case studies. We retrospectively reviewed HSRs to MTX during a 12‐year period in our tertiary care pediatric center. Seven patients were evaluated for HSRs to MTX. Skin testing was positive in one of the four patients tested. One patient underwent successful graded challenge to MTX. Seventeen desensitizations to MTX were successfully performed in the other six patients. Skin testing, graded challenge, and desensitization were safe and effective procedures in the evaluation and management of patients with HSRs to MTX in our pediatric population.
- 27 October 2016
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (5)
Methotrexate hypersensitivity reactions in pediatrics: Evaluation and management
Reports of hypersensitivity reactions (HSRs) to MTX are limited to single case studies. We retrospectively reviewed HSRs to MTX during a 12‐year period in our tertiary care pediatric center. Seven patients were evaluated for HSRs to MTX. Skin testing was positive in one of the four patients tested. One patient underwent successful graded challenge to MTX. Seventeen desensitizations to MTX were successfully performed in the other six patients. Skin testing, graded challenge, and desensitization were safe and effective procedures in the evaluation and management of patients with HSRs to MTX in our pediatric population.
- 1 September 2016
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 4 (5) , 1006-1008
Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD)
- 1 September 2016
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 4 (5) , 1006-1008
Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD)
- 1 June 2016
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 29 (2) , 91-94
Rituximab Desensitization in Pediatric Patients: Results of a Case Series
Rituximab is a monoclonal antibody (mAb) primarily used to treat oncologic and autoinflammatory conditions. Although hypersensitivity reactions (HSRs) and desensitization protocols to mAbs have been well described in adults, the experience in the pediatric population is very limited. We sought to determine the safety and efficacy of desensitization to rituximab in the pediatric population at our institution. We retrospectively reviewed the experience with HSRs and desensitization to rituximab during a 5-year period in our tertiary care pediatric center, including reaction evaluation, premedication regimens, and desensitization procedures and protocols. A total of 17 desensitizations to rituximab were performed in three patients. A 14-year-old patient underwent successful desensitization to rituximab using a published adult protocol without incident. Two younger patients (ages 7 years and 23 months) experienced significant reactions during initial desensitization attempts. Therefore, we designed a modified desensitization protocol to rituximab, with particular attention to the rate of infusion as mg/kg/h. This new patient weight-based protocol was successfully used in a total of 13 desensitizations in these two patients. Desensitization to rituximab was a safe and effective procedure in our pediatric population. We present a new patient weight-based desensitization protocol for pediatric patients who develop HSRs to rituximab, with particular usefulness for younger pediatric patients and potential utility in pediatric patients with HSRs to other mAbs.
- 1 June 2016
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 29 (2) , 91-94
Rituximab Desensitization in Pediatric Patients: Results of a Case Series
Rituximab is a monoclonal antibody (mAb) primarily used to treat oncologic and autoinflammatory conditions. Although hypersensitivity reactions (HSRs) and desensitization protocols to mAbs have been well described in adults, the experience in the pediatric population is very limited. We sought to determine the safety and efficacy of desensitization to rituximab in the pediatric population at our institution. We retrospectively reviewed the experience with HSRs and desensitization to rituximab during a 5-year period in our tertiary care pediatric center, including reaction evaluation, premedication regimens, and desensitization procedures and protocols. A total of 17 desensitizations to rituximab were performed in three patients. A 14-year-old patient underwent successful desensitization to rituximab using a published adult protocol without incident. Two younger patients (ages 7 years and 23 months) experienced significant reactions during initial desensitization attempts. Therefore, we designed a modified desensitization protocol to rituximab, with particular attention to the rate of infusion as mg/kg/h. This new patient weight-based protocol was successfully used in a total of 13 desensitizations in these two patients. Desensitization to rituximab was a safe and effective procedure in our pediatric population. We present a new patient weight-based desensitization protocol for pediatric patients who develop HSRs to rituximab, with particular usefulness for younger pediatric patients and potential utility in pediatric patients with HSRs to other mAbs.